Email: cspc@cspc.cn

Contact Us

CSPC Holdings Company Limited

News

News

Home > Media > News > VOLUNTARY ANNOUNCEMENT - Phase Ib/III Clinical Study of Sirolimus for Injection (Albumin-Bound) (HB1901) for the Treatment of Advanced Malignant Perivascular Ep

VOLUNTARY ANNOUNCEMENT - Phase Ib/III Clinical Study of Sirolimus for Injection (Albumin-Bound) (HB1901) for the Treatment of Advanced Malignant Perivascular Ep

April 20, 2026

Previous: VOLUNTARY ANNOUNCEMENT - APREPITANT INJECTION OBTAINS DRUG REGISTRATION APPROVAL

Next: VOLUNTARY ANNOUNCEMENT - SYS6051 OBTAINS CLINICAL TRIAL APPROVAL IN CHINA

Phone:

+86 311 8703 7015

Email:

Legal terms Privacy protection

Copyright © CSPC PHARMACEUTICAL GROUP LIMITED All Rights Reserved | 冀ICP备05003393号